CHEK2 (Ab-68) Antibody

What is CHEK2 and what role does it play in cancer research?

CHEK2 (Checkpoint Kinase 2, also known as CHK2) is a serine/threonine kinase that functions primarily as a tumor suppressor by mediating cell cycle arrest following DNA damage. Germline pathogenic variants in CHEK2 have been identified as conferring moderately elevated breast cancer risk with an odds ratio of approximately 2.5, which qualifies carriers for enhanced breast cancer screening protocols . The protein exhibits both proapoptotic and mitotic functions as part of the DNA damage response pathway.

CHEK2 is activated by ATM (ataxia telangiectasia mutated) kinase following the detection of double-stranded DNA breaks. Upon activation, CHEK2 is widely phosphorylated at Thr68, resulting in its activation. This phosphorylation is particularly notable during the development of precancerous lesions and in cancer progression . The constitutive activation of the DNA damage checkpoint pathway, including CHEK2, may be associated with increased levels of p53 alterations in cancer, given that p53 is a downstream target of both ATM and CHEK2.

What are the common applications for CHEK2 antibodies in research?

CHEK2 antibodies are versatile tools that serve multiple critical functions in cancer and cell biology research. Based on extensive application data, CHEK2 antibodies are most commonly employed in the following techniques:

These applications enable researchers to investigate CHEK2 expression, activation, localization, and interactions with other proteins in the DNA damage response pathway . When studying CHEK2 in cancer tissues, researchers often examine both total CHEK2 and phosphorylated CHEK2 to assess activation status of this important checkpoint protein.

How do expression patterns of CHEK2 differ across normal and cancer tissues?

CHEK2 expression patterns show significant variation between different tissue types and cancer subtypes. Immunohistochemical analyses have revealed important distinctions in both the level and subcellular localization of CHEK2 between different cancer types.

In gastric carcinoma studies, researchers have observed differential expression patterns between conventional gastric carcinoma (CGC) and early-onset gastric carcinoma (EOGC). High cytoplasmic CHEK2 expression was predominant in the CGC subtype, observed in 63% of cases, while phosphorylated CHEK2 was highly expressed in the nuclei of CGC in 53% of cases compared to only 34% in EOGC samples .

When researchers stratified samples based on nuclear CHEK2 expression levels, additional significant differences emerged:

These distinct expression patterns may reflect different biological mechanisms underlying these cancer subtypes and highlight the importance of examining both total and phosphorylated CHEK2 in cancer research.

How can CHEK2 antibodies be used to characterize variants of uncertain significance (VUS)?

CHEK2 antibodies play a crucial role in functional characterization of CHEK2 variants of uncertain significance (VUS), which is essential for determining their clinical relevance. Researchers have developed complementary functional assays that quantify the catalytic activity of CHEK2 in human cell lines to assess the impact of these variants.

One comprehensive study by the ENIGMA consortium characterized 460 unique CHEK2 missense VUS identified in 15 countries by establishing two complementary functional assays in human, diploid, non-transformed RPE1 cells with CHEK2 knockout. These assays measured:

• Phosphorylation of KAP1 at S473, an established substrate of CHEK2

• CHK2 autophosphorylation at S516

Using high-content microscopy, researchers could quantitatively measure CHEK2 activity by detecting these phosphorylation events in cells transfected with plasmids coding for EGFP-tagged CHEK2 variants . Low phosphorylation levels indicated functional impairment, while normal phosphorylation suggested the variant retained normal activity.

This approach allows researchers to stratify VUS based on functional impact and subsequently conduct case-control analyses to correlate functional categorization with actual cancer risk in carriers. For optimal results, researchers should use specific antibodies against both total CHEK2 and phospho-specific antibodies that recognize the active form of the protein.

What are the technical considerations for interpreting CHEK2 subcellular localization?

The subcellular localization of CHEK2 provides valuable insights into its activation status and function, but interpreting these patterns requires careful experimental design and consideration of several technical factors:

• Dynamic redistribution following DNA damage: Prior to DNA damage, CHEK2 is primarily associated with chromatin. Upon exposure to irradiation or topoisomerase inhibitors, phosphorylated CHEK2 is released from chromatin and accumulates in both soluble cytoplasmic and soluble nuclear fractions . This dynamic redistribution is functionally significant and must be considered when interpreting localization data.

• Nuclear vs. cytoplasmic signals: Both unphosphorylated and phosphorylated forms of CHEK2 can be detected in both nuclear and cytoplasmic compartments. Studies have shown that in human cells exposed to DNA-damaging agents, activated CHEK2 rapidly redistributes throughout the nucleus, spreading the checkpoint arrest signal from localized sites of DNA damage to soluble mobile proteins such as Cdc25 or p53 .

• Time-dependent changes: The localization pattern can change over time after DNA damage. Research has documented increased levels of phospho-CHEK2 in the cytoplasmic fraction 24 and 48 hours after treatment with DNA-damaging agents like mitoxantrone, while only weak signals were observed in the nuclear fraction at the same time points .

• Cancer-type differences: Different cancer types show distinctive patterns of CHEK2 localization. For example, in conventional gastric carcinoma, nuclear phospho-CHEK2 is more prevalent than in early-onset gastric carcinoma . These differences may have both diagnostic and biological significance.

When examining CHEK2 localization, researchers should consider co-staining with other markers of cellular compartments and use controls to validate the specificity of antibody signals in both nuclear and cytoplasmic regions.

How do functional CHEK2 assays correlate with clinical cancer risk assessment?

Functional assays using CHEK2 antibodies provide critical information that bridges laboratory findings with clinical risk assessment. Recent large-scale studies have demonstrated how these assays can help stratify cancer risk for carriers of different CHEK2 variants.

The ENIGMA consortium study collected 12 case-control datasets encompassing 161,706 patients with breast cancer and population-matched controls from 10 countries to examine breast cancer risk for carriers of functionally stratified CHEK2 missense variants . This approach allowed researchers to correlate functional impairment observed in laboratory assays with actual cancer risk in patient populations.

Specifically, the study used human RPE1-CHEK2-knockout cells transfected with plasmids encoding wild-type or variant CHEK2. By quantifying KAP1 phosphorylation and CHK2 autophosphorylation through immunodetection, researchers could categorize variants based on their functional impact. These categorizations were then applied to analyze breast cancer risk in a massive dataset of 73,048 female patients with breast cancer and 88,658 ethnicity-matched controls .

This approach demonstrates how antibody-based functional assays can help classify CHEK2 variants into categories with different associated cancer risks, providing clinically actionable information for variants previously classified as VUS. For researchers studying CHEK2 variants, incorporating both structural and functional analyses with large-scale clinical data provides the most comprehensive assessment of variant pathogenicity.

What are the recommended protocols for optimizing CHEK2 antibody detection in different applications?

Optimizing CHEK2 antibody detection requires application-specific approaches. Here are detailed recommendations for different common applications:

Western Blot (WB) Protocol Optimization:

• Recommended dilution: 1:500-1:1000

• Expected molecular weight: Calculated 61 kDa, observed 65 kDa

• Positive controls: HL-60 cells, HeLa cells, HepG2 cells

• Special considerations: CHEK2 can exist as dimers, ensure complete denaturation; include phosphatase inhibitors in lysis buffer if detecting phosphorylated forms

Immunoprecipitation (IP) Protocol:

• Recommended antibody amount: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

• Validated cell line: HeLa cells

• Considerations: Crosslinking antibody to beads may improve results when subsequently probing for CHEK2

Immunofluorescence (IF)/ICC Protocol:

• Recommended dilution: 1:50-1:500

• Validated cell line: HepG2 cells

• Fixation method: 4% paraformaldehyde for 15 minutes

• Permeabilization: 0.2% Triton X-100 in PBS for 7 minutes

• Blocking: 3% BSA in PBS at room temperature

• Counterstain: DAPI for nuclear visualization

• Incubation: Antibody incubation for 2 hours at room temperature

For all applications, researchers should perform titration experiments to determine the optimal antibody concentration for their specific experimental system and sample type.

How should researchers approach CHEK2 detection in phosphorylation studies?

Detecting phosphorylated CHEK2 requires special considerations beyond those for total CHEK2 detection:

• Sample preparation: When studying phosphorylated forms of CHEK2, samples must be collected with phosphatase inhibitors present in all buffers. Even brief exposure to endogenous phosphatases can significantly reduce signal.

• Antibody selection: Use phospho-specific antibodies targeting key sites:

  • Phospho-S516-CHK2 antibody (e.g., Cell Signaling Technology #2669)

  • Phospho-Thr68-CHK2 antibody (a key regulatory site)

• Positive controls: Include samples from cells treated with DNA-damaging agents known to activate CHEK2:

  • Ionizing radiation (IR) significantly increases KAP1-pS473 signal in parental RPE1 cells

  • Treatment with topoisomerase inhibitors

• Dual immunostaining approach: In microscopy applications, co-stain for both total and phosphorylated CHEK2 to determine the proportion of activated protein. This allows normalization of phospho-signal to total protein.

• Time-course experiments: Consider that CHEK2 phosphorylation is dynamic:

  • Increased levels of phospho-CHEK2 in the cytoplasmic fraction appear after 24 and 48 hours of mitoxantrone treatment

  • Initial phosphorylation events occur rapidly after DNA damage

• Subcellular fractionation: For detailed analysis, separate nuclear and cytoplasmic fractions before immunoblotting, as phospho-CHEK2 redistributes between these compartments following DNA damage .

The constitutive activation of CHEK2 through phosphorylation can serve as a potential marker of active CHEK2 status in cancer tissues, and immunohistochemical detection of phosphorylated protein may provide useful diagnostic information .

What controls should be included when using CHEK2 antibodies in research?

Proper controls are essential for reliable interpretation of CHEK2 antibody results. Researchers should include the following controls based on application:

Positive Controls:

• Cell lines with confirmed CHEK2 expression: HL-60, HeLa, and HepG2 cells have been validated for CHEK2 detection

• DNA damage-induced samples: Cells treated with ionizing radiation or topoisomerase inhibitors show increased CHEK2 activation

• Recombinant CHEK2 protein: For antibody validation and as a positive control in immunoblotting

Negative Controls:

• CHEK2-knockout cells: RPE1-CHEK2-KO cells or other CHEK2-null cells provide excellent negative controls

• Secondary antibody-only controls: Essential for immunofluorescence to assess background

• Isotype controls: Use matched isotype IgG for immunoprecipitation negative controls

Specificity Controls:

• Peptide competition assay: Pre-incubation of the antibody with the immunizing peptide should abolish specific signal

• Multiple antibodies targeting different epitopes: Concordant results with different antibodies increase confidence in specificity

Technical Controls:

• Loading controls for Western blot (e.g., PCNA, as used in referenced studies)

• Nuclear markers when assessing subcellular localization (e.g., DAPI co-staining)

When studying phosphorylated CHEK2, include samples treated with lambda phosphatase as a control to confirm the phospho-specificity of the antibody. For transfection experiments with CHEK2 variants, include both wild-type CHEK2 and empty vector controls for proper comparison .

How can researchers troubleshoot common issues with CHEK2 antibody applications?

When working with CHEK2 antibodies, researchers may encounter several common issues. Here are troubleshooting approaches for specific problems:

Weak or No Signal in Western Blot:

• Verify protein transfer by Ponceau S staining of membrane

• Increase antibody concentration (try 1:500 instead of 1:1000)

• Extend primary antibody incubation time or temperature (overnight at 4°C)

• Ensure sample preparation preserves CHEK2 (add protease inhibitors)

• For phospho-CHEK2, confirm activation of DNA damage response pathway

• The observed molecular weight is 65 kDa, slightly higher than calculated (61 kDa)

High Background in Immunofluorescence:

• Increase blocking time or concentration (try 5% BSA instead of 3%)

• Dilute primary antibody further (try 1:200 instead of 1:50)

• Include 0.1% Tween-20 in wash buffers

• Reduce secondary antibody concentration

• Test different fixation methods if autofluorescence is an issue

Inconsistent Subcellular Localization:

• Verify fixation method is appropriate (4% paraformaldehyde for 15 minutes)

• Use 0.2% Triton X-100 in PBS for 7 minutes for permeabilization

• Consider the timing after DNA damage, as CHEK2 localization is dynamic

• Compare with published patterns (nuclear vs. cytoplasmic distribution)

• Co-stain with markers of nuclear and cytoplasmic compartments

Failed Immunoprecipitation:

• Increase antibody amount (up to 4.0 μg for 1.0-3.0 mg of total protein lysate)

• Verify antibody-bead binding efficiency

• Extend incubation time

• Use gentler lysis conditions to preserve protein-protein interactions

• For co-immunoprecipitation, consider crosslinking to stabilize transient interactions

For all applications, sample-dependent optimization is often necessary, and researchers should titrate antibody concentrations to determine optimal conditions for their specific experimental system .

How should researchers design experiments to study CHEK2 in the DNA damage response pathway?

Designing robust experiments to study CHEK2 in the DNA damage response pathway requires careful consideration of multiple factors:

Induction of DNA Damage:
Select appropriate DNA damage inducers based on research questions:

• Ionizing radiation: Causes direct double-strand breaks

• Topoisomerase inhibitors: Prevent DNA relaxation during replication

• Mitoxantrone: DNA intercalating agent that causes double-strand breaks

• UV radiation: Induces different damage patterns than ionizing radiation

Temporal Analysis:
CHEK2 activation occurs in phases following DNA damage:

• Plan sample collection at multiple time points (15 min, 1h, 6h, 24h, 48h)

• Capture both early phosphorylation events and later protein redistribution

• Studies have shown increased levels of phospho-CHEK2 in the cytoplasmic fraction at 24 and 48 hours post-treatment

Pathway Analysis:
Include analysis of upstream and downstream components:

• ATM (upstream kinase that phosphorylates CHEK2 at Thr68)

• KAP1 (downstream substrate phosphorylated at S473)

• p53 (downstream target of CHEK2)

Cell-based Systems:
Select appropriate cellular models:

• Non-transformed cell lines like RPE1 offer more physiologically relevant responses

• Consider using matched wild-type and CHEK2-knockout cells

• Patient-derived cells carrying different CHEK2 variants can provide clinically relevant insights

Detection Methods:
Combine multiple detection approaches:

For comprehensive analysis, researchers should examine both total CHEK2 and phospho-CHEK2 levels, as well as the subcellular distribution of both forms before and after DNA damage induction.

What are the best practices for studying CHEK2 variants in cancer research?

Studying CHEK2 variants in cancer research requires a multifaceted approach combining molecular, functional, and clinical analyses:

Variant Selection and Classification:

• Collect variants from clinical genetic testing, focusing on missense variants of uncertain significance (VUS)

• Include known pathogenic and benign variants as controls

• Consider population frequency data from databases like gnomAD

• Include variants from different functional domains of CHEK2

Functional Characterization:

• Establish cell-based complementation assays in CHEK2-knockout cells

• Examine key functions:

  • KAP1 phosphorylation at S473

  • CHK2 autophosphorylation at S516

  • Cell cycle checkpoint activation

  • Apoptotic response to DNA damage

Structural Analysis:

• Use computational approaches to predict impact on protein structure

• Consider impact on:

  • Kinase activity

  • Dimerization

  • Protein-protein interactions

  • Nuclear localization

Clinical Correlation:

• Conduct case-control studies with large sample sizes

• The ENIGMA consortium analyzed 73,048 female breast cancer patients and 88,658 controls

• Stratify variants based on functional data

• Calculate odds ratios for cancer risk

Technical Validation:

• Use different antibodies and detection methods

• Include wild-type CHEK2 and known pathogenic variants as controls

• Validate findings in multiple cell types

• Consider using patient-derived cells when available

The most robust approach combines these methods to provide a comprehensive assessment of variant pathogenicity. The ENIGMA consortium study exemplifies this multidisciplinary approach by analyzing 460 CHEK2 missense VUS through both functional characterization and epidemiological analysis .

How can CHEK2 antibodies be used in combination with other markers for cancer research?

Combining CHEK2 antibodies with other molecular markers creates powerful research approaches for understanding cancer biology and potential therapeutic targets:

DNA Damage Response Pathway Analysis:

• Co-detect CHEK2 with upstream regulators:

  • ATM (activates CHEK2 through phosphorylation)

  • γ-H2AX (marker of DNA double-strand breaks)

  • BRCA1/BRCA2 (interact with CHEK2 in damage response)

• Examine downstream effectors:

  • p53 phosphorylation status (downstream target of CHEK2)

  • CDC25 phosphatases (regulated by CHEK2)

  • KAP1 phosphorylation at S473 (direct CHEK2 substrate)

Cell Cycle Analysis:

• Combine with cell cycle markers:

  • Cyclin B1 (G2/M transition)

  • Ki-67 (proliferation marker)

  • p21 (cell cycle arrest)

• Co-stain with cell cycle phase-specific markers to determine when CHEK2 is most active

Cancer Subtype Characterization:

• Combine with cancer-specific markers:

  • For breast cancer: ER, PR, HER2 status

  • For gastric cancer: Differentiation markers

  • Customized panels based on cancer type

• Stratify tumors based on CHEK2 expression patterns:

  • Nuclear vs. cytoplasmic distribution

  • Phosphorylated vs. unphosphorylated status

  • Studies show distinct patterns between cancer subtypes

Treatment Response Monitoring:

• Combine with apoptosis markers:

  • Cleaved caspase-3

  • PARP cleavage

  • Annexin V

• Assess DNA damage repair capacity:

  • RAD51 foci formation

  • BRCA1/2 expression

  • Comet assay results

This multimarker approach provides contextual information about CHEK2 function within the broader cellular signaling network and can reveal how CHEK2 variants or expression patterns correlate with other cancer-related pathways. By understanding these relationships, researchers can better identify potential therapeutic vulnerabilities and biomarkers for stratifying cancer patients.

What are the key technical specifications for CHEK2 antibodies?

Understanding the technical specifications of CHEK2 antibodies is essential for selecting the appropriate reagent and designing experiments:

Antibody Characteristics:

• Host/Isotype: Common CHEK2 antibodies are available as Rabbit IgG

• Format: Available as unconjugated antibodies, some may be conjugated to fluorophores

• Clonality: Both polyclonal and monoclonal antibodies are available

• Purification Method: Typically antigen affinity purification

Target Information:

• Full Name: CHK2 checkpoint homolog (S. pombe)

• Gene Symbol: CHEK2

• Gene ID (NCBI): 11200

• UniProt ID: O96017

• Calculated Molecular Weight: 61 kDa

• Observed Molecular Weight: 65 kDa

Reactivity and Applications:

• Tested Reactivity: human, mouse, rat

• Validated Applications: WB, IHC, IF/ICC, IP, ELISA

• Positive Control Cell Lines: HL-60 cells, HeLa cells, HepG2 cells

Production Information:

• Immunogen: Typically CHEK2 fusion proteins or synthetic peptides corresponding to specific regions of CHEK2

• Some antibodies target specific phosphorylation sites, such as phospho-S516-CHK2

Storage and Stability:

• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3

• Storage Conditions: Store at -20°C. Stable for one year after shipment

• Aliquoting: May be unnecessary for -20°C storage

• Some formulations may contain 0.1% BSA

When selecting a CHEK2 antibody, researchers should consider the specific application, species reactivity, and whether they need to detect total CHEK2 or phosphorylated forms at specific sites.

What are the recommended storage and handling practices for CHEK2 antibodies?

Proper storage and handling of CHEK2 antibodies is critical for maintaining their performance and extending their usable lifespan:

Storage Conditions:

• Temperature: Store at -20°C for long-term storage

• Buffer Composition: Typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Aliquoting: While some formulations may not require aliquoting for -20°C storage, it is generally recommended to minimize freeze-thaw cycles

• Stability: Properly stored antibodies should remain stable for one year after shipment

Handling Recommendations:

• Avoid repeated freeze-thaw cycles

  • If frequent use is anticipated, prepare working aliquots

  • Store small volumes (5-20 μL) in separate tubes

• Allow antibody to equilibrate to room temperature before opening the vial

  • This prevents condensation which can dilute the antibody solution

• Centrifuge briefly before opening

  • Ensures recovery of all material and prevents loss from the cap

• When diluting antibodies:

  • Use high-quality, freshly prepared buffers

  • For immunohistochemistry, prepare dilutions on the day of use

  • For Western blotting, diluted antibody can often be reused when stored at 4°C with preservatives

• Working with phospho-specific antibodies:

  • Include phosphatase inhibitors in all buffers when working with phospho-CHEK2 antibodies

  • Minimize exposure to room temperature

  • Consider adding sodium azide (0.02%) as a preservative for diluted antibody solutions

Quality Control Practices:

• Periodically test antibody performance with positive controls

• Document lot numbers and maintain records of antibody performance

• Include appropriate positive controls in each experiment

• Consider preparing a stock of positive control lysate or cells

Following these storage and handling recommendations will help ensure consistent performance of CHEK2 antibodies in research applications and maximize their usable lifetime.

What emerging applications are being developed for CHEK2 antibodies in cancer research?

CHEK2 antibodies are finding new applications in cutting-edge cancer research that extend beyond traditional detection methods:

Single-Cell Analysis:
The integration of CHEK2 antibodies with single-cell technologies is revealing heterogeneity in DNA damage responses within tumor populations. Mass cytometry (CyTOF) and imaging mass cytometry allow simultaneous detection of CHEK2 activation alongside dozens of other markers at the single-cell level, providing unprecedented resolution of pathway activation states in complex tissues.

Liquid Biopsy Development:
Researchers are exploring the use of CHEK2 antibodies to detect circulating tumor cells (CTCs) with activated DNA damage response pathways. This approach could potentially identify patients who might benefit from specific therapeutic interventions targeting the DNA damage response.

Therapeutic Response Prediction:
CHEK2 antibodies are being employed to develop predictive biomarkers for response to PARP inhibitors, platinum chemotherapy, and radiotherapy. By quantifying CHEK2 activation before and during treatment, researchers aim to identify early markers of therapeutic efficacy or resistance.

Functional Genomics Screens:
High-content imaging with CHEK2 phosphorylation-specific antibodies is being used as a readout in CRISPR-Cas9 and shRNA screens to identify genes that modulate the DNA damage response. These screens can reveal synthetic lethal interactions that may be exploited therapeutically.

Proximity Ligation Assays:
Advanced techniques like proximity ligation assays (PLA) using CHEK2 antibodies allow visualization and quantification of protein-protein interactions in situ. This approach is revealing new interactions between CHEK2 and other components of the DNA damage response machinery.

Patient Stratification Strategies:
The comprehensive characterization of CHEK2 variants through functional assays using specific antibodies is enabling more precise patient stratification for clinical trials and treatment decisions. This approach may eventually allow personalized risk assessment and intervention strategies based on specific CHEK2 variant profiles .

These emerging applications demonstrate the continued importance of CHEK2 antibodies in advancing our understanding of cancer biology and developing new diagnostic and therapeutic strategies.

How are CHEK2 antibodies contributing to personalized medicine approaches?

CHEK2 antibodies are playing an increasingly important role in advancing personalized medicine approaches for cancer patients through several key applications:

Variant Classification for Clinical Decision-Making:
The functional characterization of CHEK2 variants using antibody-based assays is helping to reclassify variants of uncertain significance (VUS), providing clinically actionable information. A comprehensive study by the ENIGMA consortium used CHEK2 antibodies to functionally characterize 460 missense variants, correlating functional impairment with breast cancer risk in over 160,000 cases and controls . This approach allows more precise risk stratification for patients carrying different CHEK2 variants.

Predictive Biomarker Development:
CHEK2 antibodies are being used to develop predictive biomarkers for response to specific therapies:

• Patients with tumors showing high phospho-CHEK2 may respond differently to DNA-damaging agents

• The subcellular localization of CHEK2, detected using specific antibodies, may predict sensitivity to certain targeted therapies

• Patterns of CHEK2 expression correlate with clinical outcomes in specific cancer subtypes

Monitoring Treatment Response:
Antibody-based detection of CHEK2 activation in tumor biopsies before and during treatment provides real-time information about treatment efficacy:

• Decreased phospho-CHEK2 may indicate effective targeting of upstream pathways

• Persistent CHEK2 activation despite treatment may indicate resistance mechanisms

• Serial biopsies analyzed with CHEK2 antibodies can guide treatment adjustments

Cancer Subtype Classification:
Different patterns of CHEK2 expression and phosphorylation have been observed across cancer subtypes:

• Conventional gastric carcinoma shows different CHEK2 expression patterns compared to early-onset gastric carcinoma

• These differences, detected using CHEK2 antibodies, may inform treatment selection

Development of Companion Diagnostics:
As CHEK2 inhibitors and other therapies targeting the DNA damage response advance through clinical development, CHEK2 antibodies are being investigated as components of companion diagnostic tests to identify patients most likely to benefit from these targeted approaches.

The continued refinement of antibody-based methods for detecting CHEK2 and its phosphorylated forms, combined with large-scale clinical studies correlating these patterns with treatment outcomes, will further enhance the role of CHEK2 in personalized cancer medicine.